Brand-name drug
Loreev price, strengths & recalls
Brand of lorazepam (generic)
Pharmacies pay $426.84 for 30 capsules of Loreev 1 mg (24 hr) extended-release capsule this week, and from $425.36 to $426.84 across its 4 priced strengths and forms. The generic, lorazepam, costs pharmacies from $1.09. It is in shortage (unavailable). It has 21 recalls on record, none ongoing. Its official label last changed on October 9, 2026.
UnavailableBrand- Fair cash price
- $501.37
- Strengths
- 4
- Makers
- 1
- Updated
- Nov 11
Loreev price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 1 mg (24 hr) extended-release capsule Brand | $14.23 | $426.84 / 30 capsules |
| 1.5 mg (24 hr) extended-release capsule Brand | $14.22 | $426.52 / 30 capsules |
| 2 mg (24 hr) extended-release capsule Brand | $14.18 | $425.36 / 30 capsules |
| 3 mg (24 hr) extended-release capsule Brand | $14.22 | $426.71 / 30 capsules |
The lowest cost per capsule is 2 mg (24 hr) extended-release capsule at $14.18. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Loreev vs generic lorazepam
GenericLorazepam pricesSupply status: shortages & recalls
Shortages
- Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)Limited Supply Available. Next Delivery and Estimated Recovery: June 2027
- Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)
- Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)Check wholesalers for inventory
- Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)Estimated recovery: TBD
- Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)Estimated recovery: TBD
- Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)Estimated recovery: TBD
- Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)Estimated recovery: TBD
- Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)Additional lots are scheduled to be manufactured. Product will be made available as it is released.
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 21 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Loreev
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use LOREEV XR safely and effectively. See full prescribing information for LOREEV XR. LOREEV XR (lorazepam) extended-release capsules, for oral use, CIV Initial U.S. Approval: 1977
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1), Drug Interactions (7)].
The use of benzodiazepines, including LOREEV XR, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing LOREEV XR and throughout treatment, assess each patient's risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2)].
The continued use of benzodiazepines, including LOREEV XR, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of LOREEV XR after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue LOREEV XR or reduce the dosage [see Dosage and Administration (2.4), Warnings and Precautions (5.3)].
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
See full prescribing information for complete boxed warning.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (5.1, 7)
The use of benzodiazepines, including LOREEV XR, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing LOREEV XR and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (5.2)
Abrupt discontinuation or rapid dosage reduction of LOREEV XR after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue LOREEV XR or reduce the dosage (2.4, 5.3)
Recent major changes (as listed on the label)
Warnings and Precautions (5.8) | 1/2023 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA214826 · Almatica
- First approved
- August 27, 2021 (5 years ago)
- Latest approved change
- January 13, 2023
- Approved label
- PDF, Jan 23, 2023
- Generic makers
- 16 approved generic applications on the market
- Last patent listed
- January 8, 2034
Loreev questions
How much does loreev cost without insurance?
Pharmacies pay about $426.84 for 30 capsules of loreev 1 mg (24 hr) extended-release capsule ($14.23 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $501.37. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Loreev?
Yes: lorazepam. Pharmacies pay from $1.09 for it. Compare lorazepam prices.
Is loreev in shortage?
Yes. 11 products are listed as in shortage or being discontinued (unavailable). See which ones.
Has loreev been recalled?
21 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the loreev label last change?
The official label was last updated on October 9, 2026 (version 6). See what changed.
Talk about loreev
No comments yet. Questions, tips, what worked for you - start the conversation.